|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GFOD2 |
Gene summary for GFOD2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GFOD2 | Gene ID | 81577 |
| Gene name | glucose-fructose oxidoreductase domain containing 2 | |
| Gene Alias | GFOD2 | |
| Cytomap | 16q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q3B7J2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 81577 | GFOD2 | LZE4T | Human | Esophagus | ESCC | 4.31e-05 | 1.69e-01 | 0.0811 |
| 81577 | GFOD2 | LZE8T | Human | Esophagus | ESCC | 2.94e-02 | 1.33e-01 | 0.067 |
| 81577 | GFOD2 | LZE24T | Human | Esophagus | ESCC | 4.55e-08 | 2.71e-01 | 0.0596 |
| 81577 | GFOD2 | P1T-E | Human | Esophagus | ESCC | 1.69e-08 | 3.98e-01 | 0.0875 |
| 81577 | GFOD2 | P2T-E | Human | Esophagus | ESCC | 7.95e-16 | 2.60e-01 | 0.1177 |
| 81577 | GFOD2 | P4T-E | Human | Esophagus | ESCC | 1.52e-11 | 2.76e-01 | 0.1323 |
| 81577 | GFOD2 | P5T-E | Human | Esophagus | ESCC | 8.63e-13 | 1.48e-01 | 0.1327 |
| 81577 | GFOD2 | P8T-E | Human | Esophagus | ESCC | 2.92e-14 | 2.33e-01 | 0.0889 |
| 81577 | GFOD2 | P10T-E | Human | Esophagus | ESCC | 7.27e-14 | 1.27e-01 | 0.116 |
| 81577 | GFOD2 | P11T-E | Human | Esophagus | ESCC | 7.43e-08 | 2.88e-01 | 0.1426 |
| 81577 | GFOD2 | P12T-E | Human | Esophagus | ESCC | 2.76e-07 | 1.60e-01 | 0.1122 |
| 81577 | GFOD2 | P15T-E | Human | Esophagus | ESCC | 4.31e-16 | 3.32e-01 | 0.1149 |
| 81577 | GFOD2 | P16T-E | Human | Esophagus | ESCC | 2.92e-08 | 1.52e-01 | 0.1153 |
| 81577 | GFOD2 | P20T-E | Human | Esophagus | ESCC | 2.34e-06 | 1.63e-01 | 0.1124 |
| 81577 | GFOD2 | P21T-E | Human | Esophagus | ESCC | 7.59e-18 | 3.73e-01 | 0.1617 |
| 81577 | GFOD2 | P22T-E | Human | Esophagus | ESCC | 1.03e-19 | 2.87e-01 | 0.1236 |
| 81577 | GFOD2 | P23T-E | Human | Esophagus | ESCC | 5.24e-23 | 4.92e-01 | 0.108 |
| 81577 | GFOD2 | P24T-E | Human | Esophagus | ESCC | 1.68e-11 | 2.36e-01 | 0.1287 |
| 81577 | GFOD2 | P26T-E | Human | Esophagus | ESCC | 3.38e-19 | 3.15e-01 | 0.1276 |
| 81577 | GFOD2 | P27T-E | Human | Esophagus | ESCC | 4.26e-16 | 2.06e-01 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00301984 | Esophagus | ESCC | extracellular matrix organization | 171/8552 | 301/18723 | 6.08e-05 | 4.67e-04 | 171 |
| GO:00430624 | Esophagus | ESCC | extracellular structure organization | 171/8552 | 302/18723 | 7.73e-05 | 5.76e-04 | 171 |
| GO:00452294 | Esophagus | ESCC | external encapsulating structure organization | 172/8552 | 304/18723 | 7.80e-05 | 5.80e-04 | 172 |
| GO:00301983 | Oral cavity | OSCC | extracellular matrix organization | 146/7305 | 301/18723 | 4.67e-04 | 2.77e-03 | 146 |
| GO:00452293 | Oral cavity | OSCC | external encapsulating structure organization | 147/7305 | 304/18723 | 5.30e-04 | 3.08e-03 | 147 |
| GO:00430623 | Oral cavity | OSCC | extracellular structure organization | 146/7305 | 302/18723 | 5.59e-04 | 3.23e-03 | 146 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GFOD2 | SNV | Missense_Mutation | c.118N>A | p.Glu40Lys | p.E40K | Q3B7J2 | protein_coding | tolerated(0.16) | benign(0.196) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| GFOD2 | SNV | Missense_Mutation | novel | c.1119C>G | p.Asn373Lys | p.N373K | Q3B7J2 | protein_coding | tolerated(0.09) | benign(0.111) | TCGA-AC-A6IX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| GFOD2 | SNV | Missense_Mutation | c.886C>G | p.Pro296Ala | p.P296A | Q3B7J2 | protein_coding | tolerated(0.71) | benign(0) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GFOD2 | SNV | Missense_Mutation | c.445N>A | p.Asp149Asn | p.D149N | Q3B7J2 | protein_coding | deleterious(0) | possibly_damaging(0.811) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GFOD2 | SNV | Missense_Mutation | novel | c.454A>G | p.Ile152Val | p.I152V | Q3B7J2 | protein_coding | tolerated(1) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GFOD2 | SNV | Missense_Mutation | novel | c.202N>G | p.Leu68Val | p.L68V | Q3B7J2 | protein_coding | deleterious(0.03) | possibly_damaging(0.893) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| GFOD2 | SNV | Missense_Mutation | novel | c.621N>T | p.Gln207His | p.Q207H | Q3B7J2 | protein_coding | tolerated(0.16) | benign(0.099) | TCGA-VS-A94W-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GFOD2 | SNV | Missense_Mutation | novel | c.112G>C | p.Glu38Gln | p.E38Q | Q3B7J2 | protein_coding | tolerated(0.59) | benign(0.017) | TCGA-VS-A9UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GFOD2 | SNV | Missense_Mutation | c.856G>T | p.Ala286Ser | p.A286S | Q3B7J2 | protein_coding | tolerated(0.45) | benign(0.003) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GFOD2 | SNV | Missense_Mutation | rs769566468 | c.413N>T | p.Ser138Leu | p.S138L | Q3B7J2 | protein_coding | tolerated(0.28) | benign(0) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |